Answers are grounded in this paper and cite their sources.
Recent advances in clinical genetic analysis, including whole-exome and whole-genome sequencing, have progressively shed light on the disease-associated factors and pathogenetic pathways of inflammatory keratinization disorders, which had long remained unknown. As a result, it has become clear that the overactivation of innate immunity (autoinflammation) in the skin is involved in the pathogenesis and pathophysiology of many inflammatory keratinization disorders. In light of this, we proposed the disease concept of "autoinflammatory keratinization disease" (AiKD) in 2017. AiKD is a comprehensive disease concept that encompasses inflammatory keratinization disorders caused by the genetically inherited overactivation of innate immunity (autoinflammation) in the skin. In AiKD, autoinflammatory processes in the epidermis, follicular epithelium, and superficial dermis due to genetic predisposing factors lead to hyperkeratosis. With the increasing elucidation of the previously unknown disease-associated factors, pathomechanisms, and pathophysiologies of inflammatory keratinization disorders, the number of disorders included in the AiKD category has been growing. Currently, many inflammatory keratinization disorders are recognized as AiKDs, including generalized pustular psoriasis and related disorders, CARD14-nonsyndromic epidermal differentiation disorder (nEDD) (previously known as pityriasis rubra pilaris type V and CARD14-associated papulosquamous eruption), nEDDs associated with mevalonate pathway-related genes (previously termed porokeratoses), hidradenitis suppurativa, NLRP1-palmoplantar EDD (previously known as familial chronic lichenoid keratosis), and POMP-nEDD (previously called KLICK syndrome). Even greater numbers of inflammatory keratinization disorders are expected to be identified as AiKDs in the future. A proper understanding of the pathomechanisms underlying AiKDs will not only facilitate the selection of appropriate therapeutic strategies but also contribute to the development of novel therapies based on the specific pathomechanisms of each AiKD. This review provides an overview of the diseases currently classified as AiKD, focusing on their clinical features, disease-associated genes, and pathogenic mechanisms. It also summarizes emerging mechanism-based therapies for each AiKD.
No takes yet. Share an insight, caveat, or question.
Masashi Akiyama (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: